Posaconazole

J Postgrad Med. 2010 Apr-Jun;56(2):163-7. doi: 10.4103/0022-3859.65281.

Abstract

Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. It is used as a first-line agent as well as for salvage therapy in invasive fungal infections including aspergillosis, oropharyngeal and esophageal candidiasis. It has a good adverse effect profile. With the rising incidence of invasive fungal infections due to the HIV pandemic and medical advancements in transplantation and cancer therapy, these features make posaconazole a valuable addition in the family of antifungal agents.

MeSH terms

  • Administration, Oral
  • Antifungal Agents / adverse effects
  • Antifungal Agents / pharmacokinetics*
  • Antifungal Agents / therapeutic use
  • Candidiasis / drug therapy*
  • Candidiasis / microbiology
  • Candidiasis / prevention & control
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Drug Resistance, Fungal
  • Humans
  • Immunocompromised Host / drug effects
  • Microbial Sensitivity Tests
  • Salvage Therapy
  • Treatment Outcome
  • Triazoles / adverse effects
  • Triazoles / pharmacokinetics*
  • Triazoles / therapeutic use

Substances

  • Antifungal Agents
  • Triazoles
  • posaconazole